The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2087-2092

  Steinman, Douglas H ^a   Curtin, Michael L ^a   Garland, Robert B ^a   Davidsen, Steven K ^a   Heyman, H Robin ^a   Holms, James H ^a   Albert, Daniel H ^a   Magoc, Terry J ^a   Nagy, Ildiko B ^a   Marcotte, Patrick A ^a   Li, Junling ^a   Morgan, Douglas W ^a   Hutchins, Charles ^a   Summers, James B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; COLLAGENASE; GELATINASE A; HYDROXAMIC ACID DERIVATIVE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; SUCCINIC ACID DERIVATIVE;

ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; INHIBITION KINETICS; MOLECULAR MODEL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

COLLAGENASES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; HYDROXAMIC ACIDS; INDICATORS AND REAGENTS; KINETICS; MATRIX METALLOPROTEINASE 8; MODELS, MOLECULAR; PHENYLALANINE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; THIOPHENES;

EID: 0032544135     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00396-5     Document Type: Article

References (22)

1. 1. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Current Pharmaceutical Design 1996, 2, 624.
2. 2. (a) Birkedal-Hansen, H. J. Periodontol. 1993, 64, 474.
3. (b) Martel-Pelletier, J.; McCollum, R.; Fujimoto, N.; Obata, K.; Cloutier, J.; Pelletier, J.; Lab. Invest. 1994, 70, 807.
4. (c) Ennis, B. W.; Matrisian, L. M. J. Neuro-Oncology 1994, 18, 105.
5. 3. Morphy, J. R.; Millican, T. A.; Porter, J. R. Curr. Med. Chem. 1995, 2, 743.
6. 4. Davidson, A. H.; Drummond, A. H.; Galloway, W. A.; Whittaker, M. Chem. and Ind. 1997, 3, 258.
7. 5. (a) Dhanaraj, V.; Ye, Q. Z.; Johnson, L. L.; Hupe, D. J.; Ortwine, D. F.; Dunbar, J. B.; Rubin, J. R.; Pavlovsky, A.; Humblet, C.; Blundell, T. L. Structure 1996, 4, 375.
8. (b) Ghose, A. K.; Rogan, M. E.; Treasurywala, A. M.; Wang, H.; Wahl, R. C.; Tomczuk, B. E.; Gowravaran, M. R.; Jaeger, E. P.; Wendoloski, J. J. J. Am. Chem. Soc. 1995, 117, 4671.
9. 6. Grams, F.; Crimmin, M.; Hinnes, L.; Huxley, P.; Pieper, M.; Tschesche, H.; Bode, W. Biochemistry 1995, 34, 14012.
10. 7. (a) Ripka, A. S.; Bohacek, R. S.; Rich, D. H. Bioorg. Med. Chem. Lett. 1998, 8, 357.
11. (b) Fairlie, D. P.; Abbenante, G.; March, D. Curr. Med. Chem. 1995, 2, 654.
12. 8. Xue, C. B.; He, X.; Roderick, J.; DeGrado, W. F.; Cherney, R. J.; Hardman, K. D.; Nelson, D. J.; Copeland, R. A.; Jaffe, B. D.; Decicco, C. P. J. Med. Chem. 1998, 41, 1745.
13. 9. Molecular Simulations, Inc., San Diego, California.
14. 10. Beckett, R. P.; Crimmin, M. J.; Davis, M. H.; Spavold, Z. Synlett 1993, 137.
15. 11. Tsunoda, T.; Ozaki, F.; Shirakata, N.; Tamaoka, Y.; Yamamoto, H.; Ito, S. Tetrahedron Lett. 1996, 37, 2463.
16. 12. Castelhano, A. L.; Billedeau, R.; Dewdney, N.; Donnelly, S.; Horne, S.; Kurz, L. J.; Liak, T. J.; Martin, R.; Uppington, R.; Yuan, Z.; Krantz, A. Bioorg. Med. Chem. Lett. 1995, 5, 1415.
17. 50 values were determined using a regression analysis of the concentration/inhibition data.
18. 13C NMR, mass spectroscopy, elemental analysis, and optical rotation.
19. 15. Miller, A.; Askew, M.; Beckett, R. P.; Bellang, C. L.; Bone, E. A.; Coates, R. E.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Martin, F. M.; Saroglou, L.; Thompson, A.; van Dijk, S. E.; Whittaker, M. Bioorg. Med. Chem. Lett. 1997, 7, 193.
20. 16. Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359.
21. 17. White, A. D.; Bocan, T. M. A.; Boxer, P. A.; Peterson, J. T.; Schrier, D. Current Pharmaceutical Design 1997, 3, 45.
22. 18. Singh, J.; Conzentino, P.; Cundy, K.; Gainor, J. A.; Gilliam, C. L.; Gordon, T. D.; Johnson, J. A.; Morgan, B. Schneider, E. D.; Wahl, R. C.; Whipple, D. A. Bioorg. Med. Chem. Lett. 1995, 5, 337.